Phylogica is a biopharmaceutical company engaged in the discovery and development of novel biopharmaceuticals directed at proteins and their interactions.

Phylogica’s proprietary technologies are the result of close collaboration between the Telethon Institute for Child Health Research in Perth (www.ichr.uwa.edu.au), Western Australia and The Fox Chase Cancer Center in Philadelphia (www.fccc.edu), US. Both research centres are recognised for their excellence in medical research.

Phylogica has discovered and developed a unique proprietary class of targeted peptide therapeutics (Phylomer^® peptides). These peptides exhibit competitive therapeutic, manufacturing, and commercial advantages over other more traditional targeted biologics such as proteins, monoclonal antibodies and most current therapeutic peptides. The hit to target ratios from Phylomer^® libraries are high and the proportion of hits which are functional, is also very high.

Phylogica has created, and validated potential therapeutic Phylomer^® drug leads against intracellular, extracellular and phenotypic targets, with affinities in the low nanomolar range. These leads can be readily enhanced by affinity maturation technologies into the picomolar range.

Phylogica has also demonstrated in-vivo efficacy for Phylomer^® peptides in animal models of stroke/traumatic brain injury, of burns, wound healing and of acute respiratory distress syndrome. The toxicity profiles are also encouraging. As these peptides are synthetic, chemical manipulation can enhance their stability, improve their solubility, prolong their in-vivo half-lives and minimise their risks of being immunogenic (property associated with adverse immune reaction).

Phylomer^® peptides are suitable for a wide range of diseases targeting proteins and their interactions. The Company is applying its unique technology to develop peptide-based therapies for inflammatory diseases and is exploring other indications via collaborations and partnerships.